CCL

Összesen 1 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM088182
035-os BibID:(WOS)000607296800019 (Scopus)85098069546
Első szerző:Nagy György
Cím:EULAR definition of difficult-to-treat rheumatoid arthritis / György Nagy, Nadia M. T. Roodenrijs, Paco M. J. Welsing, Melinda Kedves, Attila Hamar, Marlies C. van der Goes, Alison Kent, Margot Bakkers, Etienne Blaas, Ladislav Senolt, Zoltan Szekanecz, Ernest Choy, Maxime Dougados, Johannes W. G. Jacobs, Rinie Geenen, Hans W. J. Bijlsma, Angela Zink, Daniel Aletaha, Leonard Schoneveld, Piet van Riel, Loriane Gutermann, Yeliz Prior, Elena Nikiphorou, Gianfranco Ferraccioli, Georg Schett, Kimme L. Hyrich, Ulf Mueller-Ladner, Maya H. Buch, Iain B. McInnes, Désirée van der Heijde, Jacob M. van Laar
Dátum:2021
ISSN:0003-4967
Megjegyzések:Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be considered to have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking. Objective The Task Force in charge of the "Development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis" aims to create recommendations for this underserved patient group. Herein, we present the definition of difficult-to-treat RA, as the first step. Methods The Steering Committee drafted a definition with suggested terminology based on an international survey among rheumatologists. This was discussed and amended by the Task Force, including rheumatologists, nurses, health professionals and patients, at a face-to-face meeting until sufficient agreement was reached (assessed through voting). Results The following three criteria were agreed by all Task Force members as mandatory elements of the definition of difficult-to-treat RA: (1) Treatment according to European League Against Rheumatism (EULAR) recommendation and failure of ?2 biological disease-modifying antirheumatic drugs (DMARDs)/targeted synthetic DMARDs (with different mechanisms of action) after failing conventional synthetic DMARD therapy (unless contraindicated); (2) presence of at least one of the following: at least moderate disease activity; signs and/or symptoms suggestive of active disease; inability to taper glucocorticoid treatment; rapid radiographic progression; RA symptoms that are causing a reduction in quality of life; and (3) the management of signs and/or symptoms is perceived as problematic by the rheumatologist and/or the patient. Conclusions The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Annals Of The Rheumatic Diseases. - 80 : 1 (2021), p. 31-35. -
További szerzők:Roodenrijs, Nadia M. T. Welsing, Paco M. J. Kedves Melinda Hamar Attila Béla (1990-) (általános orvos) Goes, Marlies C. van der Kent, Alison Bakkers, Margôt Blaas, Etienne Senolt, Ladislav Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Choy, Ernest Dougados, Maxime Jacobs, Johannes W. G. Geenen, Rinie Bijlsma, Johannes W. Zink, Angela Aletaha, Daniel Schoneveld, Leonard Riel, Piet van Gutermann, Loriane Prior, Yeliz Nikiphorou, Elena (reumatológus) Ferraccioli, Gianfranco Schett, Georg Hyrich, Kimme L. Mueller-Ladner, Ulf Buch, Maya H. McInnes, Iain B. Heijde, Désirée van der Laar, Jacob M. van
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1